{"id":"W4382752021","doi":"10.1182/blood.2022018818","title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":119,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; BeiGene; AstraZeneca","keywords":"Ibrutinib; Medicine; Internal medicine; Hazard ratio; Adverse effect; Discontinuation; Chronic lymphocytic leukemia; Incidence (geometry); Confidence interval; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002533511,0.0003637283,0.0009701434,0.0005566831,0.00007296337,0.0000296175,0.0006171405,0.0003541683,0.0003198858],"category_scores_gemma":[0.00134767,0.0002587609,0.0002371078,0.00304386,0.0002541101,0.00009938959,0.0002052873,0.0005764632,0.0003900264],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.03580966,"about_ca_system_score_gemma":0.04239416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001939098,"about_ca_topic_score_gemma":0.0009295388,"domain_scores_codex":[0.9953049,0.0005174695,0.001260844,0.0006624456,0.001052454,0.001201926],"domain_scores_gemma":[0.9973664,0.001029788,0.0002200243,0.001102127,0.0001109795,0.0001707328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6355197,0.01340598,0.1034597,0.0203798,0.00410549,0.02845819,0.03490022,0.006288311,0.08223436,0.002975281,0.02238177,0.04589119],"study_design_scores_gemma":[0.9018461,0.003258221,0.03057617,0.001198732,0.0003906594,0.0003523862,0.0004837806,0.03306282,0.02683401,0.00009348823,0.001424872,0.0004787577],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912049,0.0005604736,0.000001280455,0.0001676752,0.0001014299,0.004401471,0.00002517414,0.0001604524,0.003377158],"genre_scores_gemma":[0.9968241,0.0005440108,0.00004495124,0.00008510926,0.0003039669,0.0005530007,0.0001832014,0.00006980707,0.001391839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2663264,"threshold_uncertainty_score":0.9999865,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02521432312752855,"score_gpt":0.303973250273012,"score_spread":0.2787589271454835,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}